{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T09:11:28Z","timestamp":1784970688338,"version":"3.55.0"},"reference-count":159,"publisher":"Spandidos Publications","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncol Lett"],"DOI":"10.3892\/ol.2022.13253","type":"journal-article","created":{"date-parts":[[2022,2,23]],"date-time":"2022-02-23T12:46:36Z","timestamp":1645620396000},"source":"Crossref","is-referenced-by-count":17,"title":["Cell\u2011based immunotherapy of glioblastoma multiforme (Review)"],"prefix":"10.3892","volume":"23","author":[{"given":"Igor","family":"Bryukhovetskiy","sequence":"first","affiliation":[{"name":"Medical Center, School of Medicine, Far Eastern Federal University, Vladivostok 690091, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2022,2,23]]},"reference":[{"key":"key20220311105817_b1-ol-23-04-13253","first-page":"91","article-title":"Newly diagnosed glioblastoma: A review on clinical management","volume":"33","author":"Lukas","year":"2019","journal-title":"Oncology (Williston Park)"},{"key":"key20220311105817_b2-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med"},{"key":"key20220311105817_b3-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1101\/gad.324301.119","article-title":"Glioblastoma stem cells: Lessons from the tumor hierarchy in a lethal cancer","volume":"33","author":"Gimple","year":"2019","journal-title":"Genes Dev"},{"key":"key20220311105817_b4-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1101\/gad.261982.115","article-title":"Cancer stem cells in glioblastoma","volume":"29","author":"Lathia","year":"2015","journal-title":"Genes Dev"},{"key":"key20220311105817_b5-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1038\/s41590-019-0433-y","article-title":"Mechanisms of immunotherapy resistance: Lessons from glioblastoma","volume":"20","author":"Jackson","year":"2019","journal-title":"Nat Immunol"},{"key":"key20220311105817_b6-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s11864-019-0619-4","article-title":"Current state of immunotherapy for treatment of glioblastoma","volume":"20","author":"McGranahan","year":"2019","journal-title":"Curr Treat Options Oncol"},{"key":"key20220311105817_b7-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1038\/s41591-018-0135-2","article-title":"Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors","volume":"24","author":"Chongsathidkiet","year":"2018","journal-title":"Nat Med"},{"key":"key20220311105817_b8-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.nec.2009.08.005","article-title":"Glioblastoma-derived mechanisms of systemic immunosuppression","volume":"21","author":"Waziri","year":"2010","journal-title":"Neurosurg Clin N Am"},{"issue":"(Pt 5)","key":"key20220311105817_b9-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1093\/brain\/aww046","article-title":"Corticosteroids compromise survival in glioblastoma","volume":"139","author":"Pitter","year":"2016","journal-title":"Brain"},{"key":"key20220311105817_b10-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1001\/jama.2013.280319","article-title":"Glioblastoma and other malignant gliomas: A clinical review","volume":"310","author":"Omuro","year":"2013","journal-title":"JAMA"},{"key":"key20220311105817_b11-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"299","DOI":"10.3322\/caac.21613","article-title":"Management of glioblastoma: State of the art and future directions","volume":"70","author":"Tan","year":"2020","journal-title":"CA Cancer J Clin"},{"key":"key20220311105817_b12-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"e000520","DOI":"10.1136\/esmoopen-2019-000520","article-title":"How we treat glioblastoma","volume":"4","author":"Weller","year":"2019","journal-title":"ESMO Open"},{"key":"key20220311105817_b13-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1200\/JOP.2017.025536","article-title":"Treatment of glioblastoma","volume":"13","author":"Nam","year":"2017","journal-title":"J Oncol Pract"},{"key":"key20220311105817_b14-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1007\/s00432-020-03187-w","article-title":"Proton therapy re-irradiation preserves health-related quality of life in large recurrent glioblastoma","volume":"146","author":"Scartoni","year":"2020","journal-title":"J Cancer Res Clin Oncol"},{"key":"key20220311105817_b15-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11060-020-03586-6","article-title":"Boron neutron capture therapy for malignant brain tumors","volume":"149","author":"Miyatake","year":"2020","journal-title":"J Neurooncol"},{"key":"key20220311105817_b16-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1186\/s12885-019-5413-y","article-title":"Phase I\/IIa study of concomitant radiotherapy with olaparib and temozolomide in unresectable or partially resectable glioblastoma: OLA-TMZ-RTE-01 trial protocol","volume":"19","author":"Lesueur","year":"2019","journal-title":"BMC Cancer"},{"key":"key20220311105817_b17-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1021\/acs.chemrestox.5b00452","article-title":"Kynurenine signaling increases DNA polymerase kappa expression and promotes genomic instability in glioblastoma cells","volume":"29","author":"Bostian","year":"2016","journal-title":"Chem Res Toxicol"},{"key":"key20220311105817_b18-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"886","DOI":"10.3390\/biomedicines9080886","article-title":"Bioactive compounds with antiglioma activity from marine species","volume":"9","author":"Khotimchenko","year":"2021","journal-title":"Biomedicines"},{"key":"key20220311105817_b19-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.soncn.2018.10.007","article-title":"Tumor treating fields: Adjuvant treatment for high-grade gliomas","volume":"34","author":"Anthony","year":"2018","journal-title":"Semin Oncol Nurs"},{"key":"key20220311105817_b20-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1080\/14737140.2020.1807949","article-title":"Treatment of recurrent glioblastoma: State-of-the-art and future perspectives","volume":"20","author":"Di Nunno","year":"2020","journal-title":"Expert Rev Anticancer Ther"},{"key":"key20220311105817_b21-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s11060-018-03064-0","article-title":"Re-irradiation for recurrent glioblastoma (GBM): A systematic review and meta-analysis","volume":"142","author":"Kazmi","year":"2019","journal-title":"J Neurooncol"},{"key":"key20220311105817_b22-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1159\/000493545","article-title":"Re-Irradiation with stereotactic radiosurgery\/radiotherapy for recurrent high-grade gliomas: Improved survival in the modern Era","volume":"96","author":"Gigliotti","year":"2018","journal-title":"Stereotact Funct Neurosurg"},{"key":"key20220311105817_b23-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"102029","DOI":"10.1016\/j.ctrv.2020.102029","article-title":"How did lomustine become standard of care in recurrent glioblastoma?","volume":"87","author":"Weller","year":"2020","journal-title":"Cancer Treat Rev"},{"key":"key20220311105817_b24-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1212\/01.wnl.0000197792.73656.c2","article-title":"PCV chemotherapy for recurrent glioblastoma","volume":"66","author":"Schmidt","year":"2006","journal-title":"Neurology"},{"key":"key20220311105817_b25-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","article-title":"The 2016 World Health organization classification of tumors of the central nervous system: A summary","volume":"131","author":"Louis","year":"2016","journal-title":"Acta Neuropathol"},{"key":"key20220311105817_b26-ol-23-04-13253","first-page":"1410","article-title":"Molecular biology of glioblastoma: Classification and mutational locations","volume":"67","author":"Soomro","year":"2017","journal-title":"J Pak Med Assoc"},{"key":"key20220311105817_b27-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.ccr.2009.12.020","article-title":"Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1","volume":"17","author":"Verhaak","year":"2010","journal-title":"Cancer Cell"},{"key":"key20220311105817_b28-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"246","DOI":"10.5114\/pjp.2019.93126","article-title":"Molecular classification of diffuse gliomas","volume":"70","author":"Jakovlevs","year":"2019","journal-title":"Pol J Pathol"},{"key":"key20220311105817_b29-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/7651_2015_245","article-title":"Microarray analysis in glioblastomas","volume":"1375","author":"Bhawe","year":"2016","journal-title":"Methods Mol Biol"},{"key":"key20220311105817_b30-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1093\/annonc\/mdx169","article-title":"Intratumoral heterogeneity: Pathways to treatment resistance and relapse in human glioblastoma","volume":"28","author":"Qazi","year":"2017","journal-title":"Ann Oncol"},{"key":"key20220311105817_b31-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.ccell.2018.04.011","article-title":"Biological role and therapeutic potential of IDH mutations in cancer","volume":"34","author":"Waitkus","year":"2018","journal-title":"Cancer Cell"},{"key":"key20220311105817_b32-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1038\/s41467-018-04448-6","article-title":"The genomic landscape of TERT promoter wildtype-IDH wildtype glioblastoma","volume":"9","author":"Diplas","year":"2018","journal-title":"Nat Commun"},{"key":"key20220311105817_b33-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"116781","DOI":"10.1016\/j.lfs.2019.116781","article-title":"Cancer stem cell (CSC) resistance drivers","volume":"234","author":"Najafi","year":"2019","journal-title":"Life Sci"},{"key":"key20220311105817_b34-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1038\/nm0797-730","article-title":"Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell","volume":"3","author":"Bonnet","year":"1997","journal-title":"Nat Med"},{"key":"key20220311105817_b35-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.bcp.2018.12.010","article-title":"Lung cancer stem cells: Origin, features, maintenance mechanisms and therapeutic targeting","volume":"160","author":"Heng","year":"2019","journal-title":"Biochem Pharmacol"},{"key":"key20220311105817_b36-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.biocel.2018.12.001","article-title":"Breast cancer stem cells: Biology and therapeutic implications","volume":"107","author":"Butti","year":"2019","journal-title":"Int J Biochem Cell Biol"},{"key":"key20220311105817_b37-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.semcancer.2017.04.009","article-title":"Ovarian cancer stem cells more questions than answers","volume":"44","author":"Ottevanger","year":"2017","journal-title":"Semin Cancer Biol"},{"key":"key20220311105817_b38-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1136\/jclinpath-2017-204739","article-title":"Cancer stem cells in colorectal cancer: A review","volume":"71","author":"Munro","year":"2018","journal-title":"J Clin Pathol"},{"key":"key20220311105817_b39-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.drup.2018.03.003","article-title":"Glioblastoma cancer stem cell biology: Potential theranostic targets","volume":"42","author":"Sharifzad","year":"2019","journal-title":"Drug Resist Updat"},{"key":"key20220311105817_b40-ol-23-04-13253","first-page":"5821","article-title":"Identification of a cancer stem cell in human brain tumors","volume":"63","author":"Singh","year":"2003","journal-title":"Cancer Res"},{"key":"key20220311105817_b41-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1038\/nature05236","article-title":"Glioma stem cells promote radioresistance by preferential activation of the DNA damage response","volume":"444","author":"Bao","year":"2006","journal-title":"Nature"},{"key":"key20220311105817_b42-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/1476-4598-10-128","article-title":"Chemoresistance of glioblastoma cancer stem cells-much more complex than expected","volume":"10","author":"Beier","year":"2011","journal-title":"Mol Cancer"},{"key":"key20220311105817_b43-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"448","DOI":"10.3390\/cancers11040448","article-title":"The Role of SVZ stem cells in glioblastoma","volume":"11","author":"Altmann","year":"2019","journal-title":"Cancers (Basel)"},{"key":"key20220311105817_b44-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.arr.2019.04.004","article-title":"Primary cilium and brain aging: Role in neural stem cells, neurodegenerative diseases and glioblastoma","volume":"52","author":"\u00c1lvarez-Satta","year":"2019","journal-title":"Ageing Res Rev"},{"key":"key20220311105817_b45-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"1758835918801169","DOI":"10.1177\/1758835918801169","article-title":"Primary cilium and glioblastoma","volume":"10","author":"\u00c1lvarez-Satta","year":"2018","journal-title":"Ther Adv Med Oncol"},{"key":"key20220311105817_b46-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.jtbi.2007.10.019","article-title":"Understanding stem cell differentiation through self-organization theory","volume":"250","author":"Qu","year":"2008","journal-title":"J Theor Biol"},{"key":"key20220311105817_b47-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1038\/s41586-018-0578-0","article-title":"Multi-axial self-organization properties of mouse embryonic stem cells into gastruloids","volume":"562","author":"Beccari","year":"2018","journal-title":"Nature"},{"key":"key20220311105817_b48-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/j.bcp.2012.10.001","article-title":"Glioblastoma cancer stem cells: Role of the microenvironment and therapeutic targeting","volume":"85","author":"Persano","year":"2013","journal-title":"Biochem Pharmacol"},{"key":"key20220311105817_b49-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/nature16071","article-title":"Brain tumour cells interconnect to a functional and resistant network","volume":"528","author":"Osswald","year":"2015","journal-title":"Nature"},{"key":"key20220311105817_b50-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"eaay1813","DOI":"10.1126\/science.aay1813","article-title":"Tumor-initiating cells establish an IL-33-TGF-beta niche signaling loop to promote cancer progression","volume":"369","author":"Taniguchi","year":"2020","journal-title":"Science"},{"key":"key20220311105817_b51-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.cell.2008.07.001","article-title":"TGFbeta in Cancer","volume":"134","author":"Massagu\u00e9","year":"2008","journal-title":"Cell"},{"key":"key20220311105817_b52-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41571-020-0403-1","article-title":"TGF\u03b2 biology in cancer progression and immunotherapy","volume":"18","author":"Derynck","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"key20220311105817_b53-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/bs.irn.2020.03.005","article-title":"Molecular determinants of the interaction between glioblastoma CD133+ cancer stem cells and the extracellular matrix","volume":"151","author":"Shevchenko","year":"2020","journal-title":"Int Rev Neurobiol"},{"key":"key20220311105817_b54-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.3892\/ol.2016.4756","article-title":"Molecular mechanisms of the effect of TGF-\u03b21 on U87 human glioblastoma cells","volume":"12","author":"Bryukhovetskiy","year":"2016","journal-title":"Oncol Lett"},{"key":"key20220311105817_b55-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"657","DOI":"10.3171\/2019.5.JNS181762","article-title":"The current state of immunotherapy for gliomas: An eye toward the future","volume":"131","author":"Fecci","year":"2019","journal-title":"J Neurosurg"},{"key":"key20220311105817_b56-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1158\/1078-0432.CCR-18-1625","article-title":"Immunotherapy for glioblastoma: Adoptive T-cell Strategies","volume":"25","author":"Choi","year":"2019","journal-title":"Clin Cancer Res"},{"key":"key20220311105817_b57-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1038\/s41593-019-0446-8","article-title":"Control of tumor-associated macrophages and T cells in glioblastoma via AHR and CD39","volume":"22","author":"Takenaka","year":"2019","journal-title":"Nat Neurosci"},{"key":"key20220311105817_b58-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"562812","DOI":"10.3389\/fcell.2020.562812","article-title":"The gut microbiota, kynurenine pathway, and immune system interaction in the development of brain cancer","volume":"8","author":"Dehhaghi","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"key20220311105817_b59-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"2566","DOI":"10.1002\/ijc.29309","article-title":"Enhanced immunosuppression by therapy-exposed glioblastoma multiforme tumor cells","volume":"136","author":"Authier","year":"2015","journal-title":"Int J Cancer"},{"key":"key20220311105817_b60-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"140","DOI":"10.3109\/07357907.2012.762780","article-title":"The etiology of treatment-related lymphopenia in patients with malignant gliomas: Modeling radiation dose to circulating lymphocytes explains clinical observations and suggests methods of modifying the impact of radiation on immune cells","volume":"31","author":"Yovino","year":"2013","journal-title":"Cancer Invest"},{"key":"key20220311105817_b61-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"5473","DOI":"10.1158\/1078-0432.CCR-11-0774","article-title":"Immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide","volume":"17","author":"Grossman","year":"2011","journal-title":"Clin Cancer Res"},{"key":"key20220311105817_b62-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s11060-019-03167-2","article-title":"Clinical observation of lymphopenia in patients with newly diagnosed glioblastoma","volume":"143","author":"Kim","year":"2019","journal-title":"J Neurooncol"},{"key":"key20220311105817_b63-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1093\/neuonc\/noq157","article-title":"Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma","volume":"13","author":"Sampson","year":"2011","journal-title":"Neuro Oncol"},{"key":"key20220311105817_b64-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s13014-019-1256-6","article-title":"Clinical predictors of radiation-induced lymphopenia in patients receiving chemoradiation for glioblastoma: Clinical usefulness of intensity-modulated radiotherapy in the immuno-oncology era","volume":"14","author":"Byun","year":"2019","journal-title":"Radiat Oncol"},{"key":"key20220311105817_b65-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/978-3-030-24100-1_8","article-title":"Immuno-oncology in the era of personalized medicine","volume":"1168","author":"Gwin","year":"2019","journal-title":"Adv Exp Med Biol"},{"key":"key20220311105817_b66-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"N15","DOI":"10.1227\/01.neu.0000499707.66337.09","article-title":"Do corticosteroids compromise survival in glioblastoma?","volume":"79","author":"Alkhalili","year":"2016","journal-title":"Neurosurgery"},{"key":"key20220311105817_b67-ol-23-04-13253","first-page":"e16","article-title":"Corticosteroids compromise survival in glioblastoma in part through their elevation of blood glucose levels","volume":"140","author":"Klement","year":"2017","journal-title":"Brain"},{"key":"key20220311105817_b68-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1038\/s41568-019-0224-7","article-title":"Brain immunology and immunotherapy in brain tumours","volume":"20","author":"Sampson","year":"2020","journal-title":"Nat Rev Cancer"},{"key":"key20220311105817_b69-ol-23-04-13253","first-page":"58","article-title":"Immunity to homologous grafted skin; The fate of skin homografts transplanted to the brain, to subcutaneous tissue, and to the anterior chamber of the eye","volume":"29","author":"Medawar","year":"1948","journal-title":"Br J Exp Pathol"},{"key":"key20220311105817_b70-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.1080\/21645515.2015.1081727","article-title":"The progress of immunotherapy for glioblastoma","volume":"11","author":"Zhou","year":"2015","journal-title":"Hum Vaccin Immunother"},{"key":"key20220311105817_b71-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/978-3-319-40764-7_12","article-title":"Microglia in Cancer: For good or for bad?","volume":"949","author":"da Fonseca","year":"2016","journal-title":"Adv Exp Med Biol"},{"key":"key20220311105817_b72-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.3892\/ol.2016.4886","article-title":"Cancer stem cells and microglia in the processes of glioblastoma multiforme invasive growth","volume":"12","author":"Bryukhovetskiy","year":"2016","journal-title":"Oncol Lett"},{"key":"key20220311105817_b73-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/978-1-4939-8712-2_9","article-title":"Morphological and functional analysis of CNS-associated lymphatics","volume":"1846","author":"Herz","year":"2018","journal-title":"Methods Mol Biol"},{"key":"key20220311105817_b74-ol-23-04-13253","first-page":"1462","article-title":"Nervous and lymphatic system communicate with each other. \u2018Zyka virus\u2019 unravels its mystery","volume":"11","author":"Louveau","year":"2015","journal-title":"Rev Med Suisse"},{"key":"key20220311105817_b75-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1038\/s41571-018-0003-5","article-title":"Current state of immunotherapy for glioblastoma","volume":"15","author":"Lim","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"key20220311105817_b76-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1038\/nrd.2017.158","article-title":"Immunotherapy: CAR T cells in glioblastoma","volume":"16","author":"Sarah","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"key20220311105817_b77-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"594271","DOI":"10.3389\/fimmu.2020.594271","article-title":"Chimeric antigen receptor T-cell therapy in glioblastoma: Current and future","volume":"11","author":"Li","year":"2020","journal-title":"Front Immunol"},{"key":"key20220311105817_b78-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1001\/jamaoncol.2017.0184","article-title":"HER2-specific chimeric antigen receptor-modified virus-specific T cells for progressive glioblastoma: A phase 1 dose-escalation trial","volume":"3","author":"Ahmed","year":"2017","journal-title":"JAMA Oncol"},{"key":"key20220311105817_b79-ol-23-04-13253","first-page":"25","article-title":"Heat shock proteins in cancer stem cell maintenance: A potential therapeutic target?","volume":"35","author":"Lettini","year":"2020","journal-title":"Histol Histopathol"},{"key":"key20220311105817_b80-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"5794","DOI":"10.3390\/ijms20225794","article-title":"Heat Shock Proteins in Glioblastoma Biology: Where Do We Stand?","volume":"20","author":"Iglesia","year":"2019","journal-title":"Int J Mol Sci"},{"key":"key20220311105817_b81-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1159\/000509039","article-title":"Targeting stem cells with hyperthermia: Translational relevance in cancer patients","volume":"98","author":"Ammendola","year":"2020","journal-title":"Oncol"},{"key":"key20220311105817_b82-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/nrclinonc.2016.67","article-title":"A second chance for telomerase reverse transcriptase in anticancer immunotherapy","volume":"14","author":"Zanetti","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"key20220311105817_b83-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1002\/ijc.30182","article-title":"Association of WT1 IgG antibody against WT1 peptide with prolonged survival in glioblastoma multiforme patients vaccinated with WT1 peptide","volume":"139","author":"Oji","year":"2016","journal-title":"Int J Cancer"},{"key":"key20220311105817_b84-ol-23-04-13253","first-page":"61","article-title":"Wilms' tumor 1 is involved in tumorigenicity of glioblastoma by regulating cell proliferation and apoptosis","volume":"34","author":"Kijima","year":"2014","journal-title":"Anticancer Res"},{"key":"key20220311105817_b85-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s11060-006-9220-3","article-title":"Expression of nine tumour antigens in a series of human glioblastoma multiforme:: Interest of EGFRvIII, IL-13Ralpha2, gp100 and TRP-2 for immunotherapy","volume":"81","author":"Saikali","year":"2007","journal-title":"J Neurooncol"},{"key":"key20220311105817_b86-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1097\/00002371-200307000-00002","article-title":"Molecular and functional analysis of tyrosinase-related protein (TRP)-2 as a cytotoxic T lymphocyte target in patients with malignant glioma","volume":"26","author":"Liu","year":"2003","journal-title":"J Immunother"},{"key":"key20220311105817_b87-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.omtn.2020.02.005","article-title":"Targeting ephrin receptor tyrosine kinase A2 with a selective aptamer for glioblastoma stem cells","volume":"20","author":"Affinito","year":"2020","journal-title":"Mol Ther Nucleic Acids"},{"key":"key20220311105817_b88-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"5023","DOI":"10.1158\/0008-5472.CAN-18-0267","article-title":"Cotargeting ephrin receptor tyrosine kinases A2 and A3 in cancer stem cells reduces growth of recurrent glioblastoma","volume":"78","author":"Qazi","year":"2018","journal-title":"Cancer Res"},{"key":"key20220311105817_b89-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1111\/j.1750-3639.2009.00269.x","article-title":"A2B5 cells from human glioblastoma have cancer stem cell properties","volume":"20","author":"Tchoghandjian","year":"2010","journal-title":"Brain Pathol"},{"key":"key20220311105817_b90-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.3390\/cancers11091267","article-title":"Glycolipids recognized by A2B5 antibody promote proliferation, migration, and clonogenicity in glioblastoma cells","volume":"11","author":"Baeza-Kallee","year":"2019","journal-title":"Cancers (Basel)"},{"key":"key20220311105817_b91-ol-23-04-13253","first-page":"312","article-title":"Role of SOX family of transcription factors in central nervous system tumors","volume":"4","author":"De la Rocha","year":"2014","journal-title":"Am J Cancer Res"},{"key":"key20220311105817_b92-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"3565","DOI":"10.1158\/1078-0432.CCR-20-0176","article-title":"Glioblastoma-mediated immune dysfunction limits CMV-specific T cells and therapeutic responses: Results from a phase I\/II trial","volume":"26","author":"Weathers","year":"2020","journal-title":"Clin Cancer Res"},{"key":"key20220311105817_b93-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1080\/21645515.2020.1757989","article-title":"Viral gene delivery vectors: The next generation medicines for immune-related diseases","volume":"17","author":"De Haan","year":"2021","journal-title":"Hum Vaccin Immunother"},{"key":"key20220311105817_b94-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"E2","DOI":"10.3171\/2020.11.FOCUS20854","article-title":"Viral therapies for glioblastoma and high-grade gliomas in adults: A systematic review","volume":"50","author":"Wang","year":"2021","journal-title":"Neurosurg Focus"},{"key":"key20220311105817_b95-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1056\/NEJMoa1716435","article-title":"Recurrent Glioblastoma treated with Recombinant Poliovirus","volume":"379","author":"Desjardins","year":"2018","journal-title":"N Engl J Med"},{"key":"key20220311105817_b96-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.stem.2019.11.015","article-title":"Outer Radial Glia-like cancer stem cells contribute to heterogeneity of glioblastoma","volume":"26","author":"Bhaduri","year":"2020","journal-title":"Cell Stem Cell"},{"key":"key20220311105817_b97-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1126\/science.1254257","article-title":"Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma","volume":"344","author":"Patel","year":"2014","journal-title":"Science"},{"key":"key20220311105817_b98-ol-23-04-13253","first-page":"3207","article-title":"Cancer stem cell markers in glioblastoma-an update","volume":"21","author":"Xu","year":"2017","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"key20220311105817_b99-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s11060-017-2379-y","article-title":"Molecular markers in glioma","volume":"134","author":"Ludwig","year":"2017","journal-title":"J Neurooncol"},{"key":"key20220311105817_b100-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neuint.2014.03.005","article-title":"Glioblastoma cancer stem cells: Biomarker and therapeutic advances","volume":"71","author":"Pointer","year":"2014","journal-title":"Neurochem Int"},{"key":"key20220311105817_b101-ol-23-04-13253","first-page":"e3439","article-title":"CD133 expression in glioblastoma multiforme: A literature review","volume":"10","author":"Ahmed","year":"2018","journal-title":"Cureus"},{"key":"key20220311105817_b102-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"701","DOI":"10.2741\/e280","article-title":"CD133 negative cancer stem cells in glioblastoma","volume":"3","author":"Beier","year":"2011","journal-title":"Front Biosci (Elite Ed)"},{"key":"key20220311105817_b103-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1093\/neuonc\/now258","article-title":"Hypoxia in the glioblastoma microenvironment: Shaping the phenotype of cancer stem-like cells","volume":"19","author":"Colwell","year":"2017","journal-title":"Neuro Oncol"},{"key":"key20220311105817_b104-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"S151","DOI":"10.3727\/096368914X684907","article-title":"To the novel paradigm of proteome-based cell therapy of tumors: Through comparative proteome mapping of tumor stem cells and tissue-specific stem cells of humans","volume":"23","author":"Bryukhovetskiy","year":"2014","journal-title":"Cell Transplant"},{"key":"key20220311105817_b105-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/bs.irn.2020.03.007","article-title":"Transforming growth factor-\u03b2 mimics the key proteome properties of CD133-differentiated and CD133+ cancer stem cells in glioblastoma","volume":"151","author":"Bryukhovetskiy","year":"2020","journal-title":"Int Rev Neurobiol"},{"key":"key20220311105817_b106-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/BF00177482","article-title":"Autologous tumor cell vaccination combined with adoptive cellular immunotherapy in patients with grade III\/IV astrocytoma","volume":"27","author":"Holladay","year":"1996","journal-title":"J Neurooncol"},{"key":"key20220311105817_b107-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1023\/A:1006456421177","article-title":"A pilot study of autologous cancer cell vaccination and cellular immunotherapy using anti-CD3 stimulated lymphocytes in patients with recurrent grade III\/IV astrocytoma","volume":"48","author":"Wood","year":"2000","journal-title":"J Neurooncol"},{"key":"key20220311105817_b108-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1158\/2326-6066.CIR-14-0100","article-title":"Severe adverse immunologic reaction in a patient with glioblastoma receiving autologous dendritic cell vaccines combined with GM-CSF and dose-intensified temozolomide","volume":"3","author":"Mitchell","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"key20220311105817_b109-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1056\/NEJMoa1610497","article-title":"Regression of glioblastoma after chimeric antigen receptor T-cell therapy","volume":"375","author":"Brown","year":"2016","journal-title":"N Engl J Med"},{"key":"key20220311105817_b110-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"N33","DOI":"10.1093\/neuros\/nyx105","article-title":"Use of chimeric antigen receptor T cells as a potential therapeutic for glioblastoma","volume":"80","author":"Babar Khan","year":"2017","journal-title":"Neurosurgery"},{"key":"key20220311105817_b111-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1186\/s12967-020-02598-0","article-title":"Chimeric antigen receptor T-cell therapy in glioblastoma: Charging the T cells to fight","volume":"18","author":"Land","year":"2020","journal-title":"J Transl Med"},{"key":"key20220311105817_b112-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1080\/14712598.2020.1727436","article-title":"CAR T cells and checkpoint inhibition for the treatment of glioblastoma","volume":"20","author":"Shen","year":"2020","journal-title":"Expert Opin Biol Ther"},{"key":"key20220311105817_b113-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s40263-019-00687-3","article-title":"Potential of glioblastoma-targeted chimeric antigen receptor (CAR) T-cell therapy","volume":"34","author":"Salinas","year":"2020","journal-title":"CNS Drugs"},{"key":"key20220311105817_b114-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1093\/neuonc\/nox182","article-title":"Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma","volume":"20","author":"Bielamowicz","year":"2018","journal-title":"Neuro Oncol"},{"key":"key20220311105817_b115-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"603","DOI":"10.2217\/imt.15.39","article-title":"Rindopepimut vaccine and bevacizumab combination therapy: Improving survival rates in relapsed glioblastoma patients?","volume":"7","author":"Neagu","year":"2015","journal-title":"Immunotherapy"},{"key":"key20220311105817_b116-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1016\/S1470-2045(17)30517-X","article-title":"Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): A randomised, double-blind, international phase 3 trial","volume":"18","author":"Weller","year":"2017","journal-title":"Lancet Oncol"},{"key":"key20220311105817_b117-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1080\/14712598.2017.1299705","article-title":"Prospect of rindopepimut in the treatment of glioblastoma","volume":"17","author":"Elsamadicy","year":"2017","journal-title":"Expert Opin Biol Ther"},{"key":"key20220311105817_b118-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1016\/S1470-2045(17)30619-8","article-title":"ACT IV: The final act for rindopepimut?","volume":"18","author":"Gerstner","year":"2017","journal-title":"Lancet Oncol"},{"key":"key20220311105817_b119-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s11060-005-9058-0","article-title":"Technical hurdles in a pilot clinical trial of combined B7-2 and GM-CSF immunogene therapy for glioblastomas and melanomas","volume":"78","author":"Parney","year":"2006","journal-title":"J Neurooncol"},{"key":"key20220311105817_b120-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/bs.irn.2020.03.027","article-title":"Pro-inflammatory modification of cancer cells microsurroundings increases the survival rates for rats with low differentiated malignant glioma of brain","volume":"151","author":"Zaitsev","year":"2020","journal-title":"Int Rev Neurobiol"},{"key":"key20220311105817_b121-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1007\/s00262-013-1453-3","article-title":"Therapeutic vaccination against autologous cancer stem cells with mRNA-transfected dendritic cells in patients with glioblastoma","volume":"62","author":"Vik-Mo","year":"2013","journal-title":"Cancer Immunol Immunother"},{"key":"key20220311105817_b122-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"331","DOI":"10.2217\/cns.13.29","article-title":"Vaccine-based immunotherapy for glioblastoma","volume":"2","author":"Thomas","year":"2013","journal-title":"CNS Oncol"},{"key":"key20220311105817_b123-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.wneu.2018.08.202","article-title":"Vaccine-Based immunotherapeutics for the treatment of glioblastoma: Advances, challenges, and future perspectives","volume":"120","author":"Cuoco","year":"2018","journal-title":"World Neurosurg"},{"key":"key20220311105817_b124-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/bs.ircmb.2019.07.006","article-title":"The role of dendritic cells in cancer","volume":"348","author":"Lee","year":"2019","journal-title":"Int Rev Cell Mol Biol"},{"key":"key20220311105817_b125-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s00281-016-0616-7","article-title":"The development of dendritic cell vaccine-based immunotherapies for glioblastoma","volume":"39","author":"Reardon","year":"2017","journal-title":"Semin Immunopathol"},{"key":"key20220311105817_b126-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/j.jocn.2010.11.034","article-title":"A phase I\/II clinical trial investigating the adverse and therapeutic effects of a postoperative autologous dendritic cell tumor vaccine in patients with malignant glioma","volume":"18","author":"Chang","year":"2011","journal-title":"J Clin Neurosci"},{"key":"key20220311105817_b127-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1093\/neuonc\/noq142","article-title":"Targeted therapy for high-grade glioma with the TGF-\u03b22 inhibitor trabedersen: Results of a randomized and controlled phase IIb study","volume":"13","author":"Bogdahn","year":"2011","journal-title":"Neuro Oncol"},{"key":"key20220311105817_b128-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1007\/s10637-020-00910-9","article-title":"Phase 1b\/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma","volume":"38","author":"Wick","year":"2020","journal-title":"Invest New Drugs"},{"key":"key20220311105817_b129-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"109638","DOI":"10.1016\/j.cellsig.2020.109638","article-title":"Multifaceted transforming growth factor-beta (TGFbeta) signalling in glioblastoma","volume":"72","author":"Birch","year":"2020","journal-title":"Cell Signal"},{"key":"key20220311105817_b130-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s40425-017-0257-y","article-title":"Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy","volume":"5","author":"Cannarile","year":"2017","journal-title":"J Immunother Cancer"},{"key":"key20220311105817_b131-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"eaaw7843","DOI":"10.1126\/scitranslmed.aaw7843","article-title":"Dynamic changes in glioma macrophage populations after radiotherapy reveal CSF-1R inhibition as a strategy to overcome resistance","volume":"12","author":"Akkari","year":"2020","journal-title":"Sci Transl Med"},{"key":"key20220311105817_b132-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1038\/ni.2035","article-title":"T cell exhaustion","volume":"12","author":"Wherry","year":"2011","journal-title":"Nat Immunol"},{"key":"key20220311105817_b133-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/25785826.2019.1698261","article-title":"Memory T cell, exhaustion, and tumor immunity","volume":"43","author":"Ando","year":"2020","journal-title":"Immunol Med"},{"key":"key20220311105817_b134-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"4187","DOI":"10.1158\/1078-0432.CCR-17-2617","article-title":"Immunophenotyping of newly diagnosed and recurrent glioblastoma defines distinct immune exhaustion profiles in peripheral and tumor-infiltrating lymphocytes","volume":"24","author":"Mohme","year":"2018","journal-title":"Clin Cancer Res"},{"key":"key20220311105817_b135-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"5347","DOI":"10.3390\/ijms20215347","article-title":"PD-L1\/PD-1 axis in glioblastoma multiforme","volume":"20","author":"Litak","year":"2019","journal-title":"Int J Mol Sci"},{"key":"key20220311105817_b136-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"3165","DOI":"10.1158\/1078-0432.CCR-12-3314","article-title":"Gliomas promote immunosuppression through induction of B7-H1 expression in tumor-associated macrophages","volume":"19","author":"Bloch","year":"2013","journal-title":"Clin Cancer Res"},{"key":"key20220311105817_b137-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1038\/s41591-018-0339-5","article-title":"Neoadjuvant nivolumab modifies the tumor immune microenvironment in resectable glioblastoma","volume":"25","author":"Schalper","year":"2019","journal-title":"Nat Med"},{"key":"key20220311105817_b138-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s13046-019-1085-3","article-title":"Challenges and potential of PD-1\/PD-L1 checkpoint blockade immunotherapy for glioblastoma","volume":"38","author":"Wang","year":"2019","journal-title":"J Exp Clin Cancer Res"},{"key":"key20220311105817_b139-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"506","DOI":"10.3389\/fphar.2019.00506","article-title":"Harnessing Microglia and macrophages for the treatment of glioblastoma","volume":"10","author":"Prionisti","year":"2019","journal-title":"Front Pharmacol"},{"key":"key20220311105817_b140-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1158\/2326-6066.CIR-18-0865","article-title":"Tumor vessel normalization, immunostimulatory reprogramming, and improved survival in glioblastoma with combined inhibition of PD-1, Angiopoietin-2, and VEGF","volume":"7","author":"Di Tacchio","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"key20220311105817_b141-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1097\/PPO.0000000000000326","article-title":"Bevacizumab and glioblastoma: Past, present, and future directions","volume":"24","author":"Kim","year":"2018","journal-title":"Cancer J"},{"key":"key20220311105817_b142-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1001\/jamaoncol.2020.1024","article-title":"Effect of nivolumab vs. bevacizumab in patients with recurrent glioblastoma: The CheckMate 143 Phase 3 randomized clinical trial","volume":"6","author":"Reardon","year":"2020","journal-title":"JAMA Oncol"},{"key":"key20220311105817_b143-ol-23-04-13253","first-page":"300060520951395","article-title":"Anti-PD-1, anti-VEGF, and temozolomide therapy in a patient with recurrent glioblastoma: A case report","volume":"48","author":"Chen","year":"2020","journal-title":"J Int Med Res"},{"key":"key20220311105817_b144-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1080\/21645515.2017.1388481","article-title":"Vaccination in the immunotherapy of glioblastoma","volume":"14","author":"Kong","year":"2018","journal-title":"Hum Vaccin Immunother"},{"key":"key20220311105817_b145-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.critrevonc.2019.03.019","article-title":"Immune check-point in glioblastoma multiforme","volume":"138","author":"De Felice","year":"2019","journal-title":"Crit Rev Oncol Hematol"},{"key":"key20220311105817_b146-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.cytogfr.2017.07.002","article-title":"Immunotherapy targeting immune check-point(s) in brain metastases","volume":"36","author":"Di Giacomo","year":"2017","journal-title":"Cytokine Growth Factor Rev"},{"key":"key20220311105817_b147-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"282","DOI":"10.2174\/1568009616666160813183738","article-title":"New approaches in glioblastoma multiforme: The potential role of immune-check point inhibitors","volume":"17","author":"De Felice","year":"2017","journal-title":"Curr Cancer Drug Targets"},{"key":"key20220311105817_b148-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"2334","DOI":"10.3390\/cancers12092334","article-title":"Immunotherapy for glioblastoma: Current state, challenges, and future perspectives","volume":"12","author":"Yang","year":"2020","journal-title":"Cancers (Basel)"},{"key":"key20220311105817_b149-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1093\/neuonc\/nox025","article-title":"Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: A secondary analysis of EORTC and NRG Oncology\/RTOG","volume":"19","author":"Blumenthal","year":"2017","journal-title":"Neuro Oncol"},{"key":"key20220311105817_b150-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"639","DOI":"10.3892\/or.2015.4404","article-title":"Novel cellular and post-genomic technologies in the treatment of glioblastoma multiforme (Review)","volume":"35","author":"Bryukhovetskiy","year":"2016","journal-title":"Oncol Rep"},{"key":"key20220311105817_b151-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.3389\/fimmu.2018.01004","article-title":"Immune microenvironment in glioblastoma subtypes","volume":"9","author":"Chen","year":"2018","journal-title":"Front Immunol"},{"key":"key20220311105817_b152-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"4511","DOI":"10.3892\/mmr.2016.5852","article-title":"Hematopoietic stem cells as a tool for the treatment of glioblastoma multiforme","volume":"14","author":"Bryukhovetskiy","year":"2016","journal-title":"Mol Med Rep"},{"key":"key20220311105817_b153-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.3892\/ol.2015.2952","article-title":"Directional migration of adult hematopoeitic progenitors to C6 glioma in vitro","volume":"9","author":"Bryukhovetskiy","year":"2015","journal-title":"Oncol Lett"},{"key":"key20220311105817_b154-ol-23-04-13253","first-page":"2595","article-title":"Interaction of hematopoietic CD34+ CD45+ stem cells and cancer cells stimulated by TGF-\u03b21 in a model of glioblastoma in vitro","volume":"40","author":"Milkina","year":"2018","journal-title":"Oncol Rep"},{"key":"key20220311105817_b155-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1182\/blood-2015-07-533588","article-title":"The hematopoietic stem cell niche in homeostasis and disease","volume":"126","author":"Calvi","year":"2015","journal-title":"Blood"},{"key":"key20220311105817_b156-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/bs.pbr.2020.09.005","article-title":"Is the ALS a motor neuron disease or a hematopoietic stem cell disease?","volume":"258","author":"Bryukhovetskiy","year":"2020","journal-title":"Prog Brain Res"},{"key":"key20220311105817_b157-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.stem.2020.03.014","article-title":"C\/EBP\u03b2-dependent epigenetic memory induces trained immunity in hematopoietic stem cells","volume":"26","author":"de Laval","year":"2020","journal-title":"Cell Stem Cell"},{"key":"key20220311105817_b158-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s12185-019-02759-y","article-title":"Autologous hematopoietic cell transplantation for acute myeloid leukemia in adults: 25 years of experience in Japan","volume":"111","author":"Yanada","year":"2020","journal-title":"Int J Hematol"},{"key":"key20220311105817_b159-ol-23-04-13253","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.clml.2018.12.010","article-title":"Hematopoietic progenitor cell mobilization for autologous stem cell transplantation in multiple myeloma in contemporary Era","volume":"19","author":"Arora","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"}],"container-title":["Oncology Letters"],"original-title":[],"deposited":{"date-parts":[[2022,3,11]],"date-time":"2022-03-11T08:58:32Z","timestamp":1646989112000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.spandidos-publications.com\/10.3892\/ol.2022.13253"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,23]]},"references-count":159,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,2,23]]}},"URL":"https:\/\/doi.org\/10.3892\/ol.2022.13253","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,23]]},"article-number":"133"}}